In a Pinch: Cefiderocol for CRAB Infections

Sara M. Karaba; Elizabeth B. Hirsch; Emily L. Heil

doi:10.1128/aac.00065-22

In a Pinch: Cefiderocol for CRAB Infections

Sara M. Karaba, Elizabeth B. Hirsch, Emily L. Heil

Research output: Contribution to journal › Article › peer-review

Abstract

Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. (https://doi.org/ 10.1128/aac.02142-21) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections treated with cefiderocol-containing versus colistin-containing regimens. Patients who received cefiderocol-containing regimens had lower 30-day mortality, though there are several limitations raised here, which make interpretation and applicability difficult.

Original language	English (US)
Journal	Antimicrobial agents and chemotherapy
Volume	66
Issue number	5
DOIs	https://doi.org/10.1128/aac.00065-22
State	Published - May 2022
Externally published	Yes

Keywords

Acinetobacter
CRAB
cefiderocol

ASJC Scopus subject areas

Pharmacology (medical)
Infectious Diseases
Pharmacology

Access to Document

10.1128/aac.00065-22

Cite this

@article{7fcbbaf631e344879d9b8526c84463c0,

title = "In a Pinch: Cefiderocol for CRAB Infections",

abstract = "Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. (https://doi.org/ 10.1128/aac.02142-21) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections treated with cefiderocol-containing versus colistin-containing regimens. Patients who received cefiderocol-containing regimens had lower 30-day mortality, though there are several limitations raised here, which make interpretation and applicability difficult.",

keywords = "Acinetobacter, CRAB, cefiderocol",

author = "Karaba, {Sara M.} and Hirsch, {Elizabeth B.} and Heil, {Emily L.}",

note = "Funding Information: Copyright {\textcopyright} 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Sara M. Karaba, [email protected]. For the article discussed, see https://doi.org/ 10.1128/AAC.02142-21. The authors declare a conflict of interest. E.B.H. has received research funding from Merck and advisory board honoraria from Melinta, MeMed, and Merck. E.L.H. consults for Wolters/ Kluwer (LexiComp). The views expressed in this article do not necessarily reflect the views of the journal or of ASM. Published 11 April 2022 Publisher Copyright: {\textcopyright} 2022 American Society for Microbiology.",

year = "2022",

month = may,

doi = "10.1128/aac.00065-22",

language = "English (US)",

volume = "66",

journal = "Antimicrobial agents and chemotherapy",

issn = "0066-4804",

publisher = "American Society for Microbiology",

number = "5",

}

TY - JOUR

T1 - In a Pinch

T2 - Cefiderocol for CRAB Infections

AU - Karaba, Sara M.

AU - Hirsch, Elizabeth B.

AU - Heil, Emily L.

N1 - Funding Information: Copyright © 2022 American Society for Microbiology. All Rights Reserved. Address correspondence to Sara M. Karaba, [email protected]. For the article discussed, see https://doi.org/ 10.1128/AAC.02142-21. The authors declare a conflict of interest. E.B.H. has received research funding from Merck and advisory board honoraria from Melinta, MeMed, and Merck. E.L.H. consults for Wolters/ Kluwer (LexiComp). The views expressed in this article do not necessarily reflect the views of the journal or of ASM. Published 11 April 2022 Publisher Copyright: © 2022 American Society for Microbiology.

PY - 2022/5

Y1 - 2022/5

N2 - Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. (https://doi.org/ 10.1128/aac.02142-21) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections treated with cefiderocol-containing versus colistin-containing regimens. Patients who received cefiderocol-containing regimens had lower 30-day mortality, though there are several limitations raised here, which make interpretation and applicability difficult.

AB - Carbapenem-resistant Acinetobacter baumannii (CRAB) can cause significant infections with limited treatment options available. Falcone et al. (https://doi.org/ 10.1128/aac.02142-21) describe a single-center retrospective study comparing clinical outcomes among patients with CRAB infections treated with cefiderocol-containing versus colistin-containing regimens. Patients who received cefiderocol-containing regimens had lower 30-day mortality, though there are several limitations raised here, which make interpretation and applicability difficult.

KW - Acinetobacter

KW - CRAB

KW - cefiderocol

UR - http://www.scopus.com/inward/record.url?scp=85130380266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130380266&partnerID=8YFLogxK

U2 - 10.1128/aac.00065-22

DO - 10.1128/aac.00065-22

M3 - Article

C2 - 35400199

AN - SCOPUS:85130380266

SN - 0066-4804

VL - 66

JO - Antimicrobial agents and chemotherapy

JF - Antimicrobial agents and chemotherapy

IS - 5

ER -

In a Pinch: Cefiderocol for CRAB Infections

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this